Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors
Key facts
- Where
- Copenhagen Oe, DenmarkSee the site
- Phase
- Phase 1
Where in Denmark
- RigshospitaletCopenhagen Oe, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Debiopharm International SA
- Trial code
- NCT04855656EU 2023-510063-35-00
- Record updated
- 28 October 2026
- Original description
The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.Read full original descriptionShow less
Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
Inclusion: Male or female and ≥12 years-of-age at the time of informed consent; Lansky performance status ≥50% for patients ≤16 years of age, or ECOG score of 0, 1, (or 2 for module 1) for patients >16 years of age; Locally advanced or metastatic resistant or refractory solid tumors; Patients <18 years of age must weigh at least 40 kg; Submission of available tumor tissue at screening or willingness to have a biopsy performed if safe and feasible; Next generation sequencing (NGS) report obtained in a CLIA-certified or equivalent laboratory demonstrating eligible tumor biomarker; CCNE1 amplification (non-equivocal) as determined by either a tumor or plasma NGS test, or FISH; FBXW7 deleterious mutations identified by either a tumor or plasma NGS test; PPP2R1A deleterious mutations identified by either a tumor or plasma NGS test; Measurable disease as per RECIST v1.1. For certain modules, patients with prostate cancer or ovarian cancer that have non-measurable disease but have elevated tumor markers (PSA or CA-125, respectively) can also be eligible; Ability to swallow and retain oral medications; Acceptable hematologic and organ function at screening; Negative pregnancy test (serum) for women of childbearing potential (WOCBP) at Screening; Resolution of all toxicities of prior therapy or surgical procedures; Any prior radiation must have been completed at least 7 days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatment.
Exclusion: Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 half-lives, whichever is shorter, prior to first dose of study drug; Major surgery within 4 weeks prior to first dose of lunresertib; Certain prior anti-cancer therapy; Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the participating patient's safety; Uncontrolled hypertension; Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol; History or current condition, therapy, or laboratory abnormality that might confound the study results or interfere with the patient's participation for the full duration of the study treatment; Patients who are pregnant or breastfeeding; Uncontrolled, symptomatic brain metastases.